Evaluation of Diydroxythracenedione (DHAD) in Patients with Refractory Small Cell Lung Cancer

Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study #8605 and an analysis of the recurrent disease data base.

KS Albain;JJ Crowley;L Hutchins;D Gandara;RM O'Bryan;DD Von Hoff;B Griffin;RB Livingston Cancer 72(4):1184-1191

Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: A Southwest Oncology Group study.

DD Von Hoff;T Chen;GM Clark;SK Callahan;R Livingston;the Southwest Cancer Treat Rep 67:403-404

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

Mitoxantrone for oat cell carcinoma of the lung: In vivo and in vitro results.

SK Callahan;DD Von Hoff;GM Clark;T Chen;J Mira;R Livingston;the Southwest ASCO, #C-594

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36